Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
LYPD3 - Head and neck squamous cell carcinoma
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
LYPD3 - TNFalpha effect on epidermal keratinocytes in the presence of NF-kappa B inhibitor: time course
LYPD3 - Interferon gamma effect on keratinocytes: time course
LYPD3 - Jun kinase inhibition effect on keratinocytes: time course
LYPD3 - Dermal papilla-induced epithelial stem cell differentiation
LYPD3 - IFN-gamma inflammatory effect on bronchial epithelial cells modulated by dexamethasone: time course
LYPD3 - Leprosy lesions
LYPD3 - Dexamethasone effect on epidermal keratinocytes in vitro: time course
LYPD3 - Asthma exacerbatory factors
LYPD3 - Tamoxifen effect on normal endometrial epithelium
LYPD3 - Tamoxifen effect on endometrioid carcinomas
LYPD3 - Breast cancer and selective estrogen receptor modulators
LYPD3 - CD4+ lymphocyte polarization into Th1 and Th2 cells in the presence of TGFbeta: time course (HG-U95A)
LYPD3 - Rhabdomyosarcoma and Ewing's sarcoma comparison
LYPD3 - NF-kappaB and phosphotidylinositol 3-kinase inhibitor treated monocytes infected with the human cytomegalovirus
LYPD3 - Hereditary spastic paraparesis
LYPD3 - 13-cis retinoic acid effect on SEB-1 sebocyte cell line
LYPD3 - Carboplatin sensitive and resistant ovarian carcinoma
LYPD3 - Metabolic syndrome response to exercise intervention (HG-95A)
LYPD3 - Ovarian cancer tumors after neo-adjuvant chemotherapy
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on